Abstract 5520
Background
Chemotherapy‐induced nausea and vomiting (CINV) continue to be a clinical problem, particularly in the delayed phase. CINV lack of control worsens the quality of life of patients and it is associated with complications increasing costs for healthcare services. CINV app is a free service addressed to patients treated with emetogenic chemotherapy (CT), empowering patients to report CINV impact in life and relevant information. This study aims to evaluate the usability and acceptability of a smartphone app to improve CINV management in patients receiving CT.
Methods
We used 4‐dimensions test (content, graphic design, navigation and clinical utility) to evaluate APP’s usability and acceptability. Clinical and technical researchers worked together to develop the app’s test. 44 oncology nurses of 33 representative Spanish hospitals were invited to participate (from 31st January to 5th April 2019) enrolling a total amount of 116 oncology patients for testing purposes. After using the app for a chemo cycle the patient was asked to fulfil an online usability test.
Results
Described in the table.Table: CN2
Average of patients that agree for each dimension
Variables | Results (%) |
---|---|
Contents | 81% |
Navigation | 79% |
Graphic design | 83% |
Utility | 90% |
N = 116 Oncology chemo patients level agreement 83% of patients consider this app useful for them and 86% believe it would help to improve CINV management. 94% of patients would recommend it to other patients.
Conclusions
The CINV app addresses main concerns for patients receiving chemotherapy such as the clinical situation and individual emetic risk of patient or complexity of the prescribed antiemetic regimen and impact of CINV in patients daily life. By soliciting feedback from oncology patients, we ensured that the app was acceptable and beneficial for them although some improvement points were suggested. Reporting of symptoms after CT enhances CINV management, self‐care, and participation without being a burden to patients, indicating that app can be used in clinical practice by patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Vifor Pharma España SL.
Funding
Vifor Pharma España SL.
Disclosure
P. Fernandez: Advisory / Consultancy, advisor activities: Vifor Pharma España. All other authors have declared no conflicts of interest.
Resources from the same session
4596 - A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis (MBM) (POLARIS)
Presenter: Michael Davies
Session: Poster Display session 3
Resources:
Abstract
1891 - Continuation of annual screening mammograms and breast-cancer mortality in women over 70
Presenter: Xabier Garcia De Albeniz
Session: Poster Display session 3
Resources:
Abstract
5587 - Introducing standardized medical procedure and dynamic decision support program in precision oncology for the community of practice
Presenter: Istvan Petak
Session: Poster Display session 3
Resources:
Abstract
4757 - Effectively using primary care givers in oncology care through capacity building, task sharing and techno-mentoring.
Presenter: Dinesh Pendharkar
Session: Poster Display session 3
Resources:
Abstract
4497 - A single institution review of capecitabine related acute admissions and cost analysis
Presenter: Gemma Dart
Session: Poster Display session 3
Resources:
Abstract
2187 - Health status of middle-aged and older cancer survivors in China: results from the China Health and Retirement Longitudinal Study (CHARLS)
Presenter: Jiarui Li
Session: Poster Display session 3
Resources:
Abstract
5101 - Crossed looks on lung cancer perception and knowledge from general public and physicians in France: results of a two-fold survey
Presenter: Céline Mascaux
Session: Poster Display session 3
Resources:
Abstract
4354 - Knowledge and perception of clinical trials (CTs) and attitude towards participation among Polish oncological patients - A pilot survey
Presenter: Artur Kotowski
Session: Poster Display session 3
Resources:
Abstract
3499 - Achieving best possible cancer treatment outcomes in care pathways through benchmarking; ABC-Benchmarking
Presenter: Anke Wind
Session: Poster Display session 3
Resources:
Abstract
2270 - Impact of 10-day Fulbright Specialist Program (FSP) and Project Pink Blue (PPB) Education Sessions on Medical Oncology knowledge among Doctors that treat cancer in Nigeria
Presenter: Mike Martin
Session: Poster Display session 3
Resources:
Abstract